<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### Database Entries (Dec 04)
Ar√©valo A, Pagotto R, et int., and Crispo M. [‚ÄúIvermectin reduces coronavirus infection in vivo: a mouse experimental model.‚Äù](/search/?article=Arevalo20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.02.363242](https://doi.org/10.1101/2020.11.02.363242).
### Database Entries (Dec 04)
Clausen TM, Sandoval DR, et int., and Esko JD. [‚ÄúSARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.‚Äù](/search/?article=Clausen20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.09.033](https://doi.org/10.1016/j.cell.2020.09.033). \[[PubMed32970989](https://www.ncbi.nlm.nih.gov/pubmed/32970989/)\] \[[PMC7489987](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489987/)\]
### Database Entries (Dec 04)
Kumar R, Khandelwal N, et int., and Kumar N. [‚ÄúEmetine as an antiviral agent suppresses SARS-CoV-2 replication by inhibitinginteraction of viral mRNAwith eIF4E: An in vitro study.‚Äù](/search/?article=Kumar20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.29.401984](https://doi.org/10.1101/2020.11.29.401984).
### [Clinical Trials (Dec 03)](/page/updates/#clinical.trials)
[21 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-03)
### Database Entries (Dec 03)
Outlaw VK, Bovier FT, et int., and Porotto M. [‚ÄúInhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.‚Äù](/search/?article=Outlaw20) _mBio_, 2020. [doi.org/10.1128/mbio.01935-20](https://doi.org/10.1128/mbio.01935-20). \[[PubMed33082259](https://www.ncbi.nlm.nih.gov/pubmed/33082259/)\] \[[PMC7587434](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587434/)\]
### Database Entries (Dec 03)
Udwadia ZF, Singh P, et int., and Tandon M. [‚ÄúEfficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.‚Äù](/search/?article=Udwadia20) _International Journal of Infectious Diseases_, 2020. [doi.org/10.1016/j.ijid.2020.11.142](https://doi.org/10.1016/j.ijid.2020.11.142). \[[PubMed33212256](https://www.ncbi.nlm.nih.gov/pubmed/33212256/)\] \[[PMC7668212](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668212/)\]

### [Published preprints - week of November 30](/page/updates/#published.preprints)
[Rosenke K](/search/?article=Rosenke20b);[Weisblum Y](/search/?article=Weisblum20);[Glasgow20](/search/?article=Glasgow20);[Xiao20](/search/?article=Xiao20);[Luban20](/search/?article=Luban20);[Liu20g](/search/?article=Liu20g)

### Database Entries (Nov 29)
de Melo GD, Lazarini F, et int., and Bourhy H. [‚ÄúAnti-COVID-19 efficacy of ivermectin in the golden hamster.‚Äù](/search/?article=Melo20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.21.392639](https://doi.org/10.1101/2020.11.21.392639).
### Database Entries (Nov 29)
Schloer S, Brunotte L, et int., and Rescher U. [‚ÄúDrug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Schloer20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.16.342410](https://doi.org/10.1101/2020.10.16.342410).
### Database Entries (Nov 29)
Touret F, Driouich J, et int., and Nougair√®de A. [‚ÄúPreclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.‚Äù](/search/?article=Touret20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.17.386904](https://doi.org/10.1101/2020.11.17.386904).
### Database Entries (Nov 29)
Wang M, Zhao Y, et int., and Hu K. [‚ÄúTreatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial.‚Äù](/search/?article=Wang20n) _Clinical Infectious Diseases_, 2020. [doi.org/10.1093/cid/ciaa1417](https://doi.org/10.1093/cid/ciaa1417). \[[PubMed32955081](https://www.ncbi.nlm.nih.gov/pubmed/32955081/)\] \[[PMC7543328](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543328/)\]
### [Clinical Trials (Nov 26)](/page/updates/#clinical.trials)
[7 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-26)
### Database Entries (Nov 26)
Simonovich VA, Burgos Pratx LD, et int., and Belloso WH. [‚ÄúA Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.‚Äù](/search/?article=Simonovich20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2031304](https://doi.org/10.1056/nejmoa2031304). [PubMed33232588](https://www.ncbi.nlm.nih.gov/pubmed/33232588/)
### Database Entries (Nov 25)
Busnadiego I, Fernbach S, et int., and Hale BG. [‚ÄúAntiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.‚Äù](/search/?article=Busnadiego20) _mBio_, 2020. [doi.org/10.1128/mbio.01928-20](https://doi.org/10.1128/mbio.01928-20). \[[PubMed32913009](https://www.ncbi.nlm.nih.gov/pubmed/32913009/)\] \[[PMC7484541](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484541/)\]
### Database Entries (Nov 25)
Jagannathan P, Andrews J, et int., and Singh U. [‚ÄúPeginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.‚Äù](/search/?article=Jagannathan20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.18.20234161](https://doi.org/10.1101/2020.11.18.20234161).

### Database Entries (Nov 24)
AlQahtani M, Abdulrahman A, et int., and Abduljalil M. [‚ÄúRandomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.‚Äù](/search/?article=AlQahtani20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.02.20224303](https://doi.org/10.1101/2020.11.02.20224303).
### Database Entries (Nov 24)
Bajpai M, Kumar S, et int., and Sarin SK. [‚ÄúEfficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial.‚Äù](/search/?article=Bajpai20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.25.20219337](https://doi.org/10.1101/2020.10.25.20219337).
### Database Entries (Nov 24)
Fu L, Ye F, et int., and Gao GF. [‚ÄúBoth Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.‚Äù](/search/?article=Fu20d) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18233-x](https://doi.org/10.1038/s41467-020-18233-x). \[[PubMed32887884](https://www.ncbi.nlm.nih.gov/pubmed/32887884/)\] \[[PMC7474075](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474075/)\]
### Database Entries (Nov 24)
Hoffman RL, Kania RS, et int., and Taggart B. [‚ÄúDiscovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.‚Äù](/search/?article=Hoffman20) _Journal of Medicinal Chemistry_, 2020. [doi.org/10.1021/acs.jmedchem.0c01063](https://doi.org/10.1021/acs.jmedchem.0c01063). \[[PubMed33054210](https://www.ncbi.nlm.nih.gov/pubmed/33054210/)\] \[[PMC7571312](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571312/)\]
### Database Entries (Nov 24)
Joyner MJ, Bruno KA, et int., and Wright RS. [‚ÄúSafety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients‚Äù](/search/?article=Joyner20c) _Mayo Clinic Proceedings_, 2020. [doi.org/10.1016/j.mayocp.2020.06.028](https://doi.org/10.1016/j.mayocp.2020.06.028). \[[PubMed32861333](https://www.ncbi.nlm.nih.gov/pubmed/32861333/)\] \[[PMC7368917](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368917/)\]

### Database Entries (Nov 23)
Clementi N, Scagnolari C, et int., and Filippini A. [‚ÄúNaringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Clementi20b) _Pharmacological Research_, 2020. [doi.org/10.1016/j.phrs.2020.105255](https://doi.org/10.1016/j.phrs.2020.105255). \[[PubMed33096221](https://www.ncbi.nlm.nih.gov/pubmed/33096221/)\] \[[PMC7574776](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574776/)\]
### [Published preprints - week of November 23](/page/updates/#published.preprints)
[Rajter JC](/search/?article=Rajter20)
### Database Entries (Nov 23)
Doi Y, Hibino M, et int., and Kondo M. [‚ÄúA Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.‚Äù](/search/?article=Doi20b) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.01897-20](https://doi.org/10.1128/aac.01897-20). \[[PubMed32958718](https://www.ncbi.nlm.nih.gov/pubmed/32958718/)\]
### Database Entries (Nov 23)
Libster R, Perez Marc G, et int., and Polack FP. [‚ÄúPrevention of severe COVID-19 in the elderly by early high-titer plasma.‚Äù](/search/?article=Libster20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.20.20234013](https://doi.org/10.1101/2020.11.20.20234013).
### Database Entries (Nov 23)
Shin YS, Lee JY, et int., and Park CM. [‚ÄúDiscovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2.‚Äù](/search/?article=Shin20) _Bioorganic & Medicinal Chemistry Letters_, 2020. [doi.org/10.1016/j.bmcl.2020.127667](https://doi.org/10.1016/j.bmcl.2020.127667). \[[PubMed33160024](https://www.ncbi.nlm.nih.gov/pubmed/33160024/)\] \[[PMC7640924](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640924/)\]
### Database Entries (Nov 23)
Xiang Y, Nambulli S, et int., and Shi Y. [‚ÄúVersatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.‚Äù](/search/?article=Xiang20) _Science_, 2020. [doi.org/10.1126/science.abe4747](https://doi.org/10.1126/science.abe4747). \[[PubMed33154108](https://www.ncbi.nlm.nih.gov/pubmed/33154108/)\]
### [Press Release (Nov 22)](/page/updates/#press.release)
[Casirivimab and imdevimab EUA fact sheet for healthcare providers](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201122.pdf)
### Database Entries (Nov 20)
Andreano E, Nicastri E, et int., and Rappuoli R. [‚ÄúExtremely potent human monoclonal antibodies from convalescent Covid-19 patients.‚Äù](/search/?article=Andreano20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.07.328302](https://doi.org/10.1101/2020.10.07.328302).
### Database Entries (Nov 20)
Bracken CJ, Lim SA, et int., and Wells JA. [‚ÄúBi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.‚Äù](/search/?article=Bracken20) _Nature Chemical Biology_, 2020. [doi.org/10.1038/s41589-020-00679-1](https://doi.org/10.1038/s41589-020-00679-1). \[[PubMed33082574](https://www.ncbi.nlm.nih.gov/pubmed/33082574/)\]
### Database Entries (Nov 20)
Tortorici MA, Beltramello M, et int., and Veesler D. [‚ÄúUltrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.‚Äù](/search/?article=Tortorici20) _Science_, 2020. [doi.org/10.1126/science.abe3354](https://doi.org/10.1126/science.abe3354). \[[PubMed32972994](https://www.ncbi.nlm.nih.gov/pubmed/32972994/)\]

### [Clinical Trials (Nov 19)](/page/updates/#clinical.trials)
[9 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-19)

### Database Entries (Nov 19)
Barnes CO, Jette CA, et int., and Bjorkman PJ. [‚ÄúSARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.‚Äù](/search/?article=Barnes20b) _Nature_, 2020. [doi.org/10.1038/s41586-020-2852-1](https://doi.org/10.1038/s41586-020-2852-1). \[[PubMed33045718](https://www.ncbi.nlm.nih.gov/pubmed/33045718/)\]
### Database Entries (Nov 19)
Van Damme E, De Meyer S, et int., and Van Loock M. [‚ÄúIn Vitro Activity of Itraconazole Against SARS-CoV-2.‚Äù](/search/?article=Damme20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.13.381194](https://doi.org/10.1101/2020.11.13.381194).
### Database Entries (Nov 19)
Gendrot M, Andreani J, et int., and Pradines B. [‚ÄúIn Vitro Antiviral Activity of Doxycycline against SARS-CoV-2.‚Äù](/search/?article=Gendrot20) _Molecules_, 2020. [doi.org/10.3390/molecules25215064](https://doi.org/10.3390/molecules25215064). \[[PubMed33142770](https://www.ncbi.nlm.nih.gov/pubmed/33142770/)\] \[[PMC7663271](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663271/)\]
### Database Entries (Nov 19)
Wang S, Peng Y, et int., and Liu D. [‚ÄúCharacterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.‚Äù](/search/?article=Wang20l) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-19568-1](https://doi.org/10.1038/s41467-020-19568-1). \[[PubMed33188207](https://www.ncbi.nlm.nih.gov/pubmed/33188207/)\] \[[PMC7666115](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666115/)\]

### [Published preprints - week of November 16](/page/updates/#published.preprints)
[Hurlburt NK](/search/?article=Hurlburt20) (_Nature Communications_); [Sacco MD](/search/?article=Sacco20) (_Science Advances_); [Zhang Q](/search/?article=Zhang20e) (_Cell Discovery_)
### Database Entries (Nov 17)
Monk PD, Marsden RJ, et int., and Rodrigues PM. [‚ÄúSafety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.‚Äù](/search/?article=Monk20) _The Lancet Respiratory Medicine_, 2020. [doi.org/10.1016/s2213-2600(20)30511-7](https://doi.org/10.1016/s2213-2600(20)30511-7). \[[PubMed33189161](https://www.ncbi.nlm.nih.gov/pubmed/33189161/)\]
### Database Entries (Nov 17)
Shi Y, Shuai L, et int., and Peng G. [‚ÄúThe Preclinical Inhibitor GS441524 in Combination with GC376 Efficaciously Inhibited the Proliferation of SARS-CoV-2 in the Mouse Respiratory Tract.‚Äù](/search/?article=Shi20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.12.380931](https://doi.org/10.1101/2020.11.12.380931).


### Database Entries (Nov 13)
Cornelissen L, Hoefsmit E, et int., and Blank CU. [‚ÄúNafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in a hamster model.‚Äù](/search/?article=Cornelissen20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.09.372375](https://doi.org/10.1101/2020.11.09.372375).
### Database Entries (Nov 13)
Feld JJ, Kandel C, et int., and Hansen B. [‚ÄúPeginterferon-lambda for the treatment of COVID-19 in outpatients.‚Äù](/search/?article=Feld20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.09.20228098](https://doi.org/10.1101/2020.11.09.20228098).
### Database Entries (Nov 13)
Lee S, Kim C, et int., and Choi YK. [‚ÄúA Novel Neutralizing Antibody Targeting Receptor Binding Domain of SARS-CoV-2.‚Äù](/search/?article=Lee20b) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-59639/v1](https://doi.org/10.21203/rs.3.rs-59639/v1).

### [Clinical Trials (Nov 12)](/page/updates/#clinical.trials)
[16 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-12)

### [Press Release (Nov 10)](/page/updates/#press.release)
[Bamlanivimab EUA Letter of Authorization](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly202011101.pdf)

### [Press Release (Nov 10)](/page/updates/#press.release)
[Bamlanivimab EUA Letter of Authorization FAQ](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly202011102.pdf)

### [Published preprints - week of November 9](/page/updates/#published.preprints)
[Beddingfield BJ](/search/?article=Beddingfield20) (_JACC Basic Transl Sci_); [Chen CZ](/search/?article=Chen20f) (_ACS Pharmacol. Transl. Sci._); [Ghahremanpour MM](/search/?article=Ghahremanpour20) (_ACS Med. Chem. Lett._); [Lou Y](/search/?article=Lou20) (_EJPS_); [Tandon R](/search/?article=Tandon20) (_Journal of Virology_)
### Database Entries (Nov 09)
Westberg M, Su Y, et int., and Lin MZ. [‚ÄúRational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases.‚Äù](/search/?article=Westberg20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.15.275891](https://doi.org/10.1101/2020.09.15.275891).
### Database Entries (Nov 07)
Chi X, Liu X, et int., and Yang W. [‚ÄúHumanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.‚Äù](/search/?article=Chi20b) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18387-8](https://doi.org/10.1038/s41467-020-18387-8). \[[PubMed32913273](https://www.ncbi.nlm.nih.gov/pubmed/32913273/)\] \[[PMC7483421](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483421/)\]
### Database Entries (Nov 07)
de Vries RD, Schmitz KS, et int., and Porotto M. [‚ÄúIntranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets.‚Äù](/search/?article=deVries20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.04.361154](https://doi.org/10.1101/2020.11.04.361154).

### [Published preprints - week of November 2](/page/updates/#published.preprints)
[Cust√≥dio TF](/search/?article=Custodio20) (_Ncomms_); [Schoof M](/search/?article=Schoof20) (_Science_); [Li W](/search/?article=Li20b) (_PNAS_); [Kreye J](/search/?article=Kreye20) (_Cell_); [Matsuyama S](/search/?article=Matsuyama20) (_JVI_)
### [Clinical Trials (Nov 05)](/page/updates/#clinical.trials)
[4 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-05)

### Database Entries (Nov 05)
Bojkova D, Bechtel M, et int., and Cinatl J. [‚ÄúAprotinin Inhibits SARS-CoV-2 Replication.‚Äù](/search/?article=Bojkova20c) _Cells_, 2020. [doi.org/10.3390/cells9112377](https://doi.org/10.3390/cells9112377). \[[PubMed33143316](https://www.ncbi.nlm.nih.gov/pubmed/33143316/)\]
### Database Entries (Nov 05)
Li Y, Cao L, et int., and Zhang X. [‚ÄúRemdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mice Models.‚Äù](/search/?article=Li20g) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.353300](https://doi.org/10.1101/2020.10.26.353300).
### Database Entries (Nov 04)
Cai Y, Xu W, et int., and Jiang S. [‚ÄúGriffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit.‚Äù](/search/?article=Cai20b) _Virologica Sinica_, 2020. [doi.org/10.1007/s12250-020-00305-3](https://doi.org/10.1007/s12250-020-00305-3). \[[PubMed33052520](https://www.ncbi.nlm.nih.gov/pubmed/33052520/)\] \[[PMC7554295](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554295/)\]
### Database Entries (Nov 04)
Weisblum Y, Schmidt F, et int., and Bieniasz PD. [‚ÄúEscape from neutralizing antibodies by SARS-CoV-2 spike protein variants.‚Äù](/search/?article=Weisblum20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.21.214759](https://doi.org/10.1101/2020.07.21.214759). \[[PubMed32743579](https://www.ncbi.nlm.nih.gov/pubmed/32743579/)\] \[[PMC7386497](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386497/)\]
### Database Entries (Nov 04)
Yuan S, Yin X, et int., and Yuen K. [‚ÄúClofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters.‚Äù](/search/?article=Yuan20e) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-86169/v1](https://doi.org/10.21203/rs.3.rs-86169/v1). \[[PubMed33052331](https://www.ncbi.nlm.nih.gov/pubmed/33052331/)\] \[[PMC7553155](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553155/)\]
### Database Entries (Nov 03)
Bakovic A, Risner K, et int., and Narayanan A. [‚ÄúBrilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2.‚Äù](/search/?article=Bakovic20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.29.352450](https://doi.org/10.1101/2020.10.29.352450).
### Database Entries (Nov 03)
Chan CE, Seah SG, et int., and Hanson BJ. [‚ÄúThe Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.‚Äù](/search/?article=Chan20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.355107](https://doi.org/10.1101/2020.10.26.355107).
### Database Entries (Nov 03)
Fu Y, Maruyama J, et int., and Allen RD. [‚ÄúProtective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model.‚Äù](/search/?article=Fu20c) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.28.359836](https://doi.org/10.1101/2020.10.28.359836).
### Database Entries (Nov 03)
Halfon P, Bestion E, et int., and Schinazi RF. [‚ÄúGNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition.‚Äù](/search/?article=Halfon20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.06.327635](https://doi.org/10.1101/2020.10.06.327635). \[[PubMed33052342](https://www.ncbi.nlm.nih.gov/pubmed/33052342/)\] \[[PMC7553169](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553169/)\]
### Database Entries (Nov 03)
Hashim HA, Maulood MF, et int., and Abdulamir AS. [‚ÄúControlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq.‚Äù](/search/?article=Hashim20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.26.20219345](https://doi.org/10.1101/2020.10.26.20219345).
### Database Entries (Nov 03)
Li T, Sun L, et int., and Shen X. [‚ÄúBromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‚Äê19: An Open‚ÄêLabel Randomized Controlled Pilot Study.‚Äù](/search/?article=Li20f) _Clinical and Translational Science_, 2020. [doi.org/10.1111/cts.12881](https://doi.org/10.1111/cts.12881). \[[PubMed32881359](https://www.ncbi.nlm.nih.gov/pubmed/32881359/)\]
### Database Entries (Nov 03)
Mellott D, Tseng C, et int., and McKerrow JH. [‚ÄúA cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells.‚Äù](/search/?article=Mellott20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.23.347534](https://doi.org/10.1101/2020.10.23.347534).
### Database Entries (Nov 03)
Rosenfeld R, Noy-Porat T, et int., and Mazor O. [‚ÄúPost-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody.‚Äù](/search/?article=Rosenfeld20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.354811](https://doi.org/10.1101/2020.10.26.354811).
### Database Entries (Nov 03)
Zandi K, Amblard F, et int., and Schinazi RF. [‚ÄúRepurposing Nucleoside Analogs for Human Coronaviruses.‚Äù](/search/?article=Zandi20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.01652-20](https://doi.org/10.1128/aac.01652-20). \[[PubMed33122172](https://www.ncbi.nlm.nih.gov/pubmed/33122172/)\]

### Database Entries (Nov 02)
Cao X, Maruyama J, et int., and Allen RD. [‚ÄúDiscovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach.‚Äù](/search/?article=Cao20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.27.316174](https://doi.org/10.1101/2020.09.27.316174).

### [Press Release (Oct 30)](/page/updates/#press.release)
[Regn-cov2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201030.pdf)

### [Clinical Trials (Oct 29)](/page/updates/#clinical.trials)
[11 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-29)

### Database Entries (Oct 29)
Chen P, Nirula A, et int., and Skovronsky DM. [‚ÄúSARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.‚Äù](/search/?article=Chen20l) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2029849](https://doi.org/10.1056/nejmoa2029849). \[[PubMed33113295](https://www.ncbi.nlm.nih.gov/pubmed/33113295/)\]
### [Press Release (Oct 28)](/page/updates/#press.release)
[Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN- COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201028.pdf)

### [Press Release (Oct 26)](/page/updates/#press.release)

[Lilly Statement Regarding NIH‚Äôs ACTIV-3 Clinical Trial](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly20201027.pdf)

### Database Entries (Oct 26)
Pan H, Peto R, et int., and Swaminathan S. [‚ÄúRepurposed antiviral drugs for COVID-19 ‚Äìinterim WHO SOLIDARITY trial results.‚Äù](/search/?article=Pan20b) _medRxiv_, 2020. [doi.org/10.1101/2020.10.15.20209817](https://doi.org/10.1101/2020.10.15.20209817).
### Database Entries (Oct 26)
Rocco PRM, Silva PL, et int., and Lapa e Silva JR. [‚ÄúEarly use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial.‚Äù](/search/?article=Rocco20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.21.20217208](https://doi.org/10.1101/2020.10.21.20217208).
